What are the management guidelines for Intrauterine Growth Restriction (IUGR) based on Royal College of Obstetricians and Gynaecologists (RCOG) and National Health Service (NHS) National Institute for Health and Care Excellence (NICE) recommendations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Intrauterine Growth Restriction (IUGR) Based on RCOG and NICE Guidelines

Umbilical artery Doppler assessment should be the cornerstone of surveillance for IUGR fetuses, with timing of delivery based on Doppler findings and gestational age to reduce perinatal mortality and morbidity. 1, 2

Diagnosis and Classification

  • IUGR is defined as an ultrasonographic estimated fetal weight (EFW) or abdominal circumference (AC) below the 10th percentile for gestational age 2
  • Classification:
    • Early-onset IUGR: diagnosed <32 weeks gestation 1
    • Late-onset IUGR: diagnosed ≥32 weeks gestation 1
    • Severe IUGR: EFW <3rd percentile 1, 2

Initial Assessment

  • Detailed obstetrical ultrasound examination should be performed when IUGR is identified, as up to 20% of cases are associated with fetal or chromosomal abnormalities 2
  • Prenatal diagnostic testing with chromosomal microarray analysis (CMA) should be offered when unexplained isolated IUGR is diagnosed at <32 weeks 1, 2
  • At first diagnosis of IUGR, assessment should include fetal biometry, amniotic fluid volume, and umbilical artery Doppler waveform analysis 1

Surveillance Protocol

For EFW 3rd-9th percentile:

  • Umbilical artery Doppler every 1-2 weeks initially; if stable, can extend to every 2-4 weeks 1
  • Cardiotocography (CTG) once per week 1
  • Consider EFW assessment every 2 weeks 1
  • Fetal growth evaluation no more frequently than every 2 weeks 1

For EFW <3rd percentile (Severe IUGR):

  • Weekly umbilical artery Doppler assessment 1
  • Weekly cardiotocography 1
  • Consider EFW assessment every 2 weeks 1

For Abnormal Umbilical Artery Doppler:

  • With decreased end-diastolic velocity (elevated PI/RI/S:D ratio >95th percentile): weekly umbilical artery Doppler evaluation 1
  • With absent end-diastolic velocity (AEDV): Doppler assessment 2-3 times per week 1
  • With reversed end-diastolic velocity (REDV): hospitalization, daily CTG monitoring, and consideration of delivery 1

Timing of Delivery Based on Doppler Findings

  • Normal umbilical artery Doppler: Consider delivery at 38-39 weeks 1, 2
  • Elevated umbilical artery indices (decreased diastolic flow): Consider delivery at >37 weeks 1, 2
  • Absent end-diastolic flow: Consider delivery at >34 weeks if surveillance remains reassuring 1
  • Reversed end-diastolic flow: Consider delivery at >32 weeks if surveillance remains reassuring 1
  • Severe IUGR (EFW <3rd percentile): Recommend delivery at 37 weeks 2

Antenatal Interventions

  • Antenatal corticosteroids should be administered between 24+0 and 34+0 weeks gestation, but may be given up until 38+0 weeks in cases of elective cesarean delivery 1
  • Antenatal corticosteroids should be administered if absent or reversed end-diastolic flow is noted at <34 weeks 1, 2
  • Close observation for 48-72 hours after corticosteroid administration is recommended, as there may be transient return of end-diastolic flow in about two-thirds of cases 1, 2
  • Magnesium sulfate for fetal neuroprotection should be administered in gestations before 32 weeks 1, 2

Mode of Delivery

  • For pregnancies with IUGR complicated by absent or reversed end-diastolic velocity, cesarean delivery should be considered based on the clinical scenario 2
  • Daily cardiotocograph monitoring is recommended with absent end-diastolic flow before 34 weeks 1
  • With reversed end-diastolic flow before 30 weeks, hospital admission with daily cardiotocograph monitoring is recommended 1

Special Considerations

  • Women with early-onset IUGR should be closely monitored for development of hypertensive disorders, as maternal hypertension is present in up to 70% of these cases at delivery 2
  • The single most important prognostic factor in preterm fetuses with growth restriction is the gestational age at delivery, with an increase of 1%-2% in intact survival for every additional day in utero up until 32 weeks 2
  • Doppler of any vessel is not recommended as a screening tool for identification of pregnancies that will subsequently be complicated by IUGR 1

Common Pitfalls and Caveats

  • Do not confuse IUGR with small for gestational age (SGA), which is simply a statistical definition without implying pathology 3
  • Avoid relying solely on estimated fetal weight for management decisions; incorporate Doppler findings which better reflect fetal compromise 4
  • Remember that IUGR fetuses are at higher risk of intrapartum compromise and may quickly decompensate once uterine contractions have started 5
  • Be aware that the optimal timing of delivery requires balancing the risks of prematurity against the risks of continued intrauterine compromise 6, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Intrauterine Growth Restriction (IUGR)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Intrauterine growth restriction - part 1.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016

Research

Doppler assessment of the intrauterine growth-restricted fetus.

Annals of the New York Academy of Sciences, 2006

Research

Intrauterine restriction (IUGR).

Journal of perinatal medicine, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.